BRAF and cancer: Based on these 19 drug-variant combinations, 4 out of 6 sensitive mutations in DEPO (KRAS G12V, BRAF V600E, NRAS Q61K, and KRAS G12D) were significantly associated with sensitivity to at least one of their paired drugs in both the cancer-type-specific and non-specific settings.